Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from EHA

Incyte Sets Mid-Year Phase 3 Trial for CALR Antibody 989 as Pipeline Updates Roll Out

Incyte (NASDAQ:INCY) Chief Medical Officer Steven Stein outlined the company’s development priorities across hematology, oncology and immunology, with a particular focus on its mutant CALR antibody 989, during a company news event. Stein said myeloproliferative neoplasms remain “front and center” f

MarketBeat · May 25

The Road To Immortality – Inside the Elite World of Life Extension

From high-tech biohacking to holistic wellness: in the race to live forever, who’s benefitting from the science of longevity – and what does health optimisation really look like?

Marie Claire · Jan 30

Biden Administration Strips Federal Funding From Nonprofit at Center of COVID Lab Leak Controversy

Federal officials say EcoHealth Alliance failed to properly report on its gain-of-function research at the Wuhan Institute of Virology and to monitor safety conditions there.

Reason · May 15, 2024

From analysis to the latest developments in health,
read the most diverse news in one place.

Liverpool Handball Club women’s team excluded from ‘Final Four’ tournament over technicality

“Overall it’s just disappointment and a bit of anger. Everyone was playing really well, and we were enjoying the season"

Liverpool Echo · Mar 24, 2023

Caribou's Lymphoma Candidate Shows 100% Response Rate In Early-Stage Study

Caribou Biosciences Inc (NASDAQ: CRBU) announced initial data from its ANTLER Phase 1 trial for CB-010 in relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL). These initial data will be shared at the European Hematology Association (EHA) 2022 Hybrid Congress.

Benzinga · May 12, 2022

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Wuhan Institute of Virology

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.